These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 34432264)

  • 1. GATA3 as a regulator for naughty cancer-associated fibroblasts in the microenvironment of high-grade serous ovarian cancer.
    El-Arabey AA; Abdalla M
    Hum Cell; 2021 Nov; 34(6):1934-1936. PubMed ID: 34432264
    [No Abstract]   [Full Text] [Related]  

  • 2. GATA3 and stemness of high-grade serous ovarian carcinoma: novel hope for the deadliest type of ovarian cancer.
    El-Arabey AA; Abdalla M; Abd-Allah AR
    Hum Cell; 2020 Jul; 33(3):904-906. PubMed ID: 32388811
    [No Abstract]   [Full Text] [Related]  

  • 3. GATA3 as a master regulator for interactions of tumor-associated macrophages with high-grade serous ovarian carcinoma.
    El-Arabey AA; Denizli M; Kanlikilicer P; Bayraktar R; Ivan C; Rashed M; Kabil N; Ozpolat B; Calin GA; Salama SA; Abd-Allah AR; Sood AK; Lopez-Berestein G
    Cell Signal; 2020 Apr; 68():109539. PubMed ID: 31935430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Complex Network of Tumor Microenvironment in Human High-Grade Serous Ovarian Cancer.
    Kreuzinger C; Geroldinger A; Smeets D; Braicu EI; Sehouli J; Koller J; Wolf A; Darb-Esfahani S; Joehrens K; Vergote I; Vanderstichele A; Boeckx B; Lambrechts D; Gabra H; Wisman GBA; Trillsch F; Heinze G; Horvat R; Polterauer S; Berns E; Theillet C; Cacsire Castillo-Tong D
    Clin Cancer Res; 2017 Dec; 23(24):7621-7632. PubMed ID: 28972047
    [No Abstract]   [Full Text] [Related]  

  • 5. Immune profiling reveals prognostic genes in high-grade serous ovarian cancer.
    Wu Y; Xia L; Zhao P; Deng Y; Guo Q; Zhu J; Chen X; Ju X; Wu X
    Aging (Albany NY); 2020 Jun; 12(12):11398-11415. PubMed ID: 32544083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of GATA3 in the metastasis of triple-negative breast cancer and high-grade serous ovarian cancer.
    El-Arabey AA; Abdalla M
    Hum Cell; 2022 Jul; 35(4):1298-1300. PubMed ID: 35459984
    [No Abstract]   [Full Text] [Related]  

  • 7. High expression of SLC7A1 in high-grade serous ovarian cancer promotes tumor progression and is involved in MAPK/ERK pathway and EMT.
    You S; Han X; Xu Y; Sui L; Song K; Yao Q
    Cancer Med; 2024 May; 13(10):e7217. PubMed ID: 38752472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ovarian Cancer-Associated Ascites Have High Proportions of Cytokine-Responsive CD56bright NK Cells.
    Tonetti CR; de Souza-Araújo CN; Yoshida A; da Silva RF; Alves PCM; Mazzola TN; Derchain S; Fernandes LGR; Guimarães F
    Cells; 2021 Jul; 10(7):. PubMed ID: 34359872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumour microenvironment-based molecular profiling reveals ideal candidates for high-grade serous ovarian cancer immunotherapy.
    Lu X; Ji C; Jiang L; Zhu Y; Zhou Y; Meng J; Gao J; Lu T; Ye J; Yan F
    Cell Prolif; 2021 Mar; 54(3):e12979. PubMed ID: 33522069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in the tumour microenvironment mark the transition from serous borderline tumour to low-grade serous carcinoma.
    Vallejos R; Zhantuyakova A; Negri GL; Martin SD; Spencer SE; Thornton S; Leung S; Lynch B; Qin Y; Chow C; Liang B; Zdravko S; Douglas JM; Milne K; Mateyko B; Nelson BH; Howitt BE; Kommoss FK; Horn LC; Hoang L; Singh N; Morin GB; Huntsman DG; Cochrane D
    J Pathol; 2024 Oct; 264(2):197-211. PubMed ID: 39081243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ubiquitin-Proteasome Axis, Especially Ubiquitin-Specific Protease-17 (
    Yildirim N; Kocal GC; Isik Z; Saatli B; Saygili U; Uysal T; Ulukus C; Koyuncuoglu M; Ellidokuz H; Basbinar Y
    Reprod Sci; 2019 Jun; 26(6):794-805. PubMed ID: 30198418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single-cell transcriptomics reveals the aggressive landscape of high-grade serous carcinoma and therapeutic targets in tumor microenvironment.
    Xu J; Lu W; Wei X; Zhang B; Yang H; Tu M; Chen X; Wu S; Guo T
    Cancer Lett; 2024 Jul; 593():216928. PubMed ID: 38714290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CXCL10 alters the tumour immune microenvironment and disease progression in a syngeneic murine model of high-grade serous ovarian cancer.
    K Au K; Peterson N; Truesdell P; Reid-Schachter G; Khalaj K; Ren R; Francis JA; Graham CH; Craig AW; Koti M
    Gynecol Oncol; 2017 Jun; 145(3):436-445. PubMed ID: 28318643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Defining three ferroptosis-based molecular subtypes and developing a prognostic risk model for high-grade serous ovarian cancer.
    Sun X; He W; Lin B; Huang W; Ye D
    Aging (Albany NY); 2024 May; 16(10):9106-9126. PubMed ID: 38795391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional balance between Tcf21-Slug defines cellular plasticity and migratory modalities in high grade serous ovarian cancer cell lines.
    Varankar SS; More M; Abraham A; Pansare K; Kumar B; Narayanan NJ; Jolly MK; Mali AM; Bapat SA
    Carcinogenesis; 2020 Jun; 41(4):515-526. PubMed ID: 31241128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Murine Oviductal High-Grade Serous Carcinomas Mirror the Genomic Alterations, Gene Expression Profiles, and Immune Microenvironment of Their Human Counterparts.
    McCool KW; Freeman ZT; Zhai Y; Wu R; Hu K; Liu CJ; Tomlins SA; Fearon ER; Magnuson B; Kuick R; Cho KR
    Cancer Res; 2020 Feb; 80(4):877-889. PubMed ID: 31806642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevated GALNT10 expression identifies immunosuppressive microenvironment and dismal prognosis of patients with high grade serous ovarian cancer.
    Zhang G; Lu J; Yang M; Wang Y; Liu H; Xu C
    Cancer Immunol Immunother; 2020 Feb; 69(2):175-187. PubMed ID: 31853576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HMGA2 and high-grade serous ovarian carcinoma.
    Wu J; Wei JJ
    J Mol Med (Berl); 2013 Oct; 91(10):1155-65. PubMed ID: 23686260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heterogeneous Tumor-Immune Microenvironments among Differentially Growing Metastases in an Ovarian Cancer Patient.
    Jiménez-Sánchez A; Memon D; Pourpe S; Veeraraghavan H; Li Y; Vargas HA; Gill MB; Park KJ; Zivanovic O; Konner J; Ricca J; Zamarin D; Walther T; Aghajanian C; Wolchok JD; Sala E; Merghoub T; Snyder A; Miller ML
    Cell; 2017 Aug; 170(5):927-938.e20. PubMed ID: 28841418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Divergent modes of clonal spread and intraperitoneal mixing in high-grade serous ovarian cancer.
    McPherson A; Roth A; Laks E; Masud T; Bashashati A; Zhang AW; Ha G; Biele J; Yap D; Wan A; Prentice LM; Khattra J; Smith MA; Nielsen CB; Mullaly SC; Kalloger S; Karnezis A; Shumansky K; Siu C; Rosner J; Chan HL; Ho J; Melnyk N; Senz J; Yang W; Moore R; Mungall AJ; Marra MA; Bouchard-Côté A; Gilks CB; Huntsman DG; McAlpine JN; Aparicio S; Shah SP
    Nat Genet; 2016 Jul; 48(7):758-67. PubMed ID: 27182968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.